Allarity Therapeutics, Inc. (ALLR) stock intrinsic value fair value estimate & owner earnings analysis

Allarity Therapeutics is a clinical-stage cancer drug developer with one product candidate. Stenoparib, licensed with worldwide rights from Eisai, blocks two enzyme families (PARP1/2 and tankyrases) that cancer cells use to survive. It is in a Phase 2 trial in heavily pre-treated, recurrent ovarian cancer, and patients are chosen with Allarity's own Drug Response Predictor (DRP) gene-expression test. The company reports one confirmed complete response and two patients with stable disease for more than 14 months. In February 2026 the first patients were dosed in a second Phase 2 trial, in relapsed small cell lung cancer. The US Department of Veterans Affairs funds that trial and runs it at 11 VA medical centers. All other programs (dovitinib, irofulven, LiPlaCis) have been dropped. Novartis ended the dovitinib license in January 2024, citing a material breach. The company has no product sales, and it has spent cash every year. Owner earnings are cash from operations with working-capital timing swings removed, stock paid to employees and consultants counted as a cost, and equipment spending deducted. On that basis they were about -$8.3M in 2020, -$26.8M in 2021, -$18.3M in 2022, -$16.0M in 2023, -$18.1M in 2024 and -$9.8M in 2025. Large non-cash items were stripped out: warrant revaluation gains of $17.1M in 2022 and $10.4M in 2023, and a $9.7M write-off of the dovitinib rights in 2024. Stock sales paid for the losses. Four reverse splits in 2023-2024 (1-for-35, 1-for-40, 1-for-20, 1-for-30) combined old shares 840,000-to-1, and the share count has since grown again from 7.3M at the end of 2024 to about 15.9M. We measure spending from 2025, the first full year as a single-product company after cost cuts that took operating expenses from $27.2M in 2024 to $12.9M. The first half of 2026 confirms that level: $5.4M of operating expenses, about $10M a year before interest. On June 30, 2026 Allarity held $17.0M of cash plus $10.0M of restricted cash. Against that it owed $20.9M on non-convertible promissory notes issued to Streeterville Capital on March 2, 2026 ($20.0M net proceeds). These are classed as due within a year, and reported interest works out to roughly 14% a year. It also owed about $5.6M to Novartis from the ended license: about $3.6M payable, about $0.6M of interest accruing at 5%, and a $1.4M convertible note, all already due. After all borrowings the company has only about $0.5M of net cash. The notes cost about 8 percentage points more than our 6% benchmark, which adds $0.6M to $3.0M to the true burden depending on how long they stay outstanding. The full terms of the notes were not in the filings we reviewed, so the rate is inferred from reported interest expense. No part of the business has secured or proven cash earnings: no approved product, no partner, no royalty. A good Phase 2 readout or a licensing deal could change that, but neither has happened, so no case gives them any value. Each case charges only the spending the company has already committed its existing resources to. Base case: stenoparib development and overhead keep costing about $10M a year before interest, and the notes fall due within about 12 months. The business is worth about -$9.7M over that period, net cash after borrowings is about +$0.5M, and the notes' above-market cost adds about $1.2M. Total: about -$10.4M, or -$0.65 a share. Bear case: interest income fades as cash is spent, so spending runs about $10.8M a year. The notes are then rolled for another year at the same roughly 14% cost. The business is worth about -$10.5M, the excess note cost is about $3.0M, and net cash is +$0.5M. Total: about -$13.0M, or -$0.82 a share. This case also leaves out a real risk: the board approved another $5M of buybacks in February 2026, after spending $3.2M on buybacks in 2025, while the company was borrowing at about 14%. Bull case: the notes are repaid early from the restricted cash (extra cost about $0.6M), and the VA carries the lung cancer trial. Existing cash has to cover only about six months at the recent spending rate (about $4.8M) before new money takes over, such as the $6M stock purchase line signed with Tumim Stone Capital in January 2026. Total: about -$4.9M, or -$0.31 a share. In all three cases the company owes more than it is worth today, by roughly $5M to $13M, once debts and committed spending are counted. Any value in the shares is an option on stenoparib's trial results that has not been earned yet. In March 2026 the company said its cash would fund operations for at least 12 months. The SEC matter over past statements about the dovitinib application was settled in March 2025 with a $2.5M penalty, paid in April 2025. A related shareholder class action was dismissed in February 2025. We would be wrong if stenoparib wins a license or partnership with meaningful up-front cash, or if ovarian cancer data lead to a funded path to approval. Either would turn the option into measurable value.